We are thrilled to share ground-breaking findings from our latest research on Kaneka Ubiquinol™, highlighting its significant benefits for cognitive health.
Participants: 90 adults aged 50-83 years, monitored over 34 weeks.
Methods: In the randomised, double-blind, placebo-controlled trial, participants were administered 100mg of Kaneka Ubiquinol™ daily. Cognitive performance was assessed using standard neuropsychological tests – Memory Performance Index (MPI), Trail Making Test (TMT) and Digit Symbol Substitution Test (DSST) were conducted.
Results: Serum ubiquinol concentration, serum ubiquinone concentration and serum total coenzyme Q10 concentration were significantly increased in the ubiquinol group compared to the placebo group (all P < 0.0001), and significant improvements in cognitive function were observed.
Measuring cognitive domains of processing speed, sequencing, mental flexibility and visual motor skills, ubiquinol intake improved memory, attentiveness and work processing ability.
Regarding cognitive function, no significant difference was observed between the two groups in MPI score, TMT-A, TMT-B, 1 (B-A) or DSST score, but the percentage of people whose values improved later tended to be higher in the ubiquinol group (62.2%) than in the placebo group (44.4%) (P=0.09).
Furthermore, among participants with a baseline MPI score of 50.2 or higher, significantly more people improved in the ubiquinol group (62.8%) than in the placebo group (41.0%) (P=0.049).
After 34 weeks, TMT-A response time in the ubiquinol group was significantly lower than that of the placebo (placebo group 32.4 seconds, ubiquinol group 28.4 seconds (P=0.0498)). Similarly, when tested TMT- B, the response times for the ubiquinol group were found to be shorter (placebo group 67.2 seconds, ubiquinol group 58.1 seconds (P=0.07)).
The fact that ubiquinol was effective in TMT suggests that ubiquinol acts on frontal lobe functions such as attention, judgment and task processing ability.
As we age, maintaining cognitive health becomes increasingly important. Ubiquinol, the active form of CoQ10, is essential for energy production in cells and offers potent antioxidant protection. This research underscores the potential of Kaneka Ubiquinol™ as a vital supplement for supporting brain health and combating age-related cognitive decline.
Connect with us on LinkedIn for regular updates on our research and products, and discover more about the benefits of Ubiquinol and how it can support your cognitive health. Or contact us for more information.
Always read the label and follow the directions for use. Consult your healthcare professional to establish if Ubiquinol is suitable for your needs.
Reference:
Kinoshita T, et al. The effects of ubiquinol (reduced form of coenzyme Q10) on memory, attentiveness, and work processing ability in healthy middled-aged and elderly residents – a randomized, double-blind, placebo-controlled trial. Jpn Pharmacol Ther 2021;49:1739-1747.
Join us at FFWS 2025 Bangkok with Kaneka Ubiquinol™ to Discuss the Science Behind Healthy…
How Kaneka Ubiquinol™ can Mitigate the Effects of Stress and Poor Sleep The events that…
In an outstanding achievement, Kaneka Ubiquinol™, the global supplier of bioidentical Ubiquinol, has been awarded the Raw…
Kaneka Ubiquinol at the Complementary Medicines Australia Conference 2024 Today, Kaneka Ubiquinol was proud to…
Webinar with Dr Ross Walker, Integrative Cardiologist Our recent webinar, A Pharmacist’s Guide to Ubiquinol’s…
Kaneka Ubiquinol™ in New Zealand for Industry Innovation The Kaneka team was proud to attend…